Global Metastatic Cancer Treatment Market

Focus on Drugs, Competitive Landscape, and Country - Analysis and Forecast (2018-2025)

Published Year: 2018
SKU: BH00597SA

4749

Online Access for One Person. Permission to Print

A quick peek into the report

Table of Contents

Request a Sample

Market Overview

1.1. Introduction to Cancer
1.2. Cancer Statistics: Incidence, Survival and Mortality
1.2.1. Important Facts
1.3. Metastasis and Metastatic Cancer
1.3.1. Where Cancer Spreads
1.3.1. Ongoing Research and Treatment of Metastatic Cancer
1.4. Global Market
1.5. FDA Approvals of Oncology Drugs
1.6. Assumptions and Limitation

Market Dynamics

2.1. Market Dynamics: Impact Analysis
2.2. Market Drivers
2.3. Market Restraints
2.4. Market Opportunities

Industry Insights

3.1. Introduction
3.2. Regulatory Scenario
3.3. Regulatory Designations
3.4. Patent Landscape

Competitive Landscape

4.1. Introduction
4.2. Key Developments and Strategies
4.2.1. Product Approvals
4.2.2. Clinical Study
4.2.3. Agreement, Partnership, Joint Venture and Collaboration
4.2.4 Regulatory Designations
4.2.5. Acquisition, Product Launches and Others
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrant
4.3.4. Threat of Substitute
4.3.5. Intensity of Competitive Rivalry 
4.4. Market Share (2014-2017)
4.5. Pipeline Analysis

Global Metastatic Cancer Treatment Market, By Therapeutic Application

5.1. Overview
5.2. Breast Cancer
5.2.1. Breast Cancer: Types, Secondary Sites and Symptoms
5.2.1.1. Breast Cancer: Molecular Subtypes
5.2.2. Breast Cancer: Incidence, Mortality and Prevalence
5.2.3 Breast Cancer: Market
5.2.4. Breast Cancer: Treatment
5.3. Melanoma
5.3.1. Melanoma: Types, Secondary Sites and Symptoms
5.3.2. Melanoma: Incidence, Mortality and Prevalence
5.3.3 Melanoma: Market
5.3.4. Melanoma: Treatment
5.4. Prostate Cancer
5.4.1. Prostate Cancer: Types, Secondary Sites and Symptoms
5.4.2. Prostate Cancer: Incidence, Mortality and Prevalence
5.4.3. Prostate Cancer: Market
5.4.4. Prostate Cancer: Treatment
5.5. Lung Cancer
5.5.1. Lung Cancer: Types, Secondary Sites and Symptoms
5.5.2. Lung Cancer: Incidence, Mortality and Prevalence
5.5.3. Lung Cancer: Market
5.5.4. Lung Cancer: Treatment
5.6. Colorectal Cancer
5.6.1. Colorectal Cancer: Types, Secondary Sites and Symptoms
5.6.2. Colorectal Cancer: Incidence, Mortality and Prevalence
5.6.3. Colorectal Cancer: Market
5.6.4. Colorectal Cancer: Treatment
5.7. Other Cancers

Global Metastatic Cancer Treatment Market, By Product

6.1. Overview
6.1.1. Generic vs. Branded Drugs 
6.2. Role of Branded Medicines in Oncology
6.2.1. Branded Medicines: Market
6.3. Role of Generic Medicines in Oncology
6.3.1. Generic Medicines: Market
6.4. Sales of Oncology Drugs 

Global Metastatic Cancer Treatment Market, By Region

7.1. Overview
7.1.1. Introduction
7.2. North America
7.2.1. The U.S.
7.2.2. Canada
7.3. Europe
7.3.1. Germany
7.3.2. The U.K.
7.3.3. France
7.3.4. Spain
7.3.5. Italy
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.5. Latin America
7.5.1. Brazil
7.5.2. Mexico
7.5.3. Argentina
7.6. Rest of the World

Company Profiles

8.1. AbbVie, Inc.
8.1.1. Overview
8.1.2. Overall Product Portfolio
8.1.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.1.3. Financials
8.1.3.1. Financial Summary
8.1.4. Global Presence
8.1.5. Recent Developments
8.1.6. SWOT Analysis
8.2. Amgen, Inc.
8.2.1. Overview
8.2.2. Overall Product Portfolio
8.2.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.2.3. Financials
8.2.3.1. Financial Summary
8.2.4. Global Presence
8.2.5. Recent Developments
8.2.6. SWOT Analysis
8.3. AstraZeneca PLC
8.3.1. Overview
8.3.2. Overall Product Portfolio
8.2.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.3.3. Financials
8.3.3.1. Financial Summary
8.3.4. Global Presence
8.3.5. Recent Developments
8.3.6. SWOT Analysis
8.4. Bayer AG
8.4.1. Overview
8.4.2. Overall Product Portfolio
8.4.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.4.3. Financials
8.4.3.1. Financial Summary
8.4.4. Global Presence
8.4.5. Recent Developments
8.4.6. SWOT Analysis
8.5. Boehringer Ingelheim International GmbH
8.5.1. Overview
8.5.2. Overall Product Portfolio
8.5.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.5.3. Financials
8.5.3.1. Financial Summary
8.5.4. Global Presence
8.5.5. Recent Developments
8.5.6. SWOT Analysis
8.6. BRISTOL-MYERS SQUIBB COMPANY
8.6.1. Overview
8.6.2. Overall Product Portfolio
8.6.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.6.3. Financials
8.6.3.1. Financial Summary
8.6.4. Global Presence
8.6.5. Recent Developments
8.6.6. SWOT Analysis
8.7. CELGENE CORPORATION
8.7.1. Overview
8.7.2. Overall Product Portfolio
8.7.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.7.3. Financials
8.7.3.1. Financial Summary
8.7.4. Global Presence
8.7.5. Recent Developments
8.7.6. SWOT Analysis
8.8. Eli-Lilly and Company
8.8.1. Overview
8.8.2. Overall Product Portfolio
8.8.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.8.3. Financials
8.8.3.1. Financial Summary
8.8.4. Global Presence
8.8.5. Recent Developments
8.8.6. SWOT Analysis
8.9. F. Hoffmann-La Roche AG
8.9.1. Overview
8.9.2. Overall Product Portfolio
8.9.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.9.3. Financials
8.9.3.1. Financial Summary
8.9.4. Global Presence
8.9.5. Recent Developments
8.9.6. SWOT Analysis
8.10. JOHNSON & JOHNSON
8.10.1. Overview
8.10.2. Overall Product Portfolio
8.10.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.10.3. Financials
8.10.3.1. Financial Summary
8.10.4. Global Presence
8.10.5. Recent Developments
8.10.6. SWOT Analysis
8.11. Merck & Co., Inc.
8.11.1. Overview
8.11.2. Overall Product Portfolio
8.11.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.11.3. Financials
8.11.3.1. Financial Summary
8.11.4. Global Presence
8.11.5. Recent Developments
8.11.6. SWOT Analysis
8.12. Novartis AG
8.12.1. Overview
8.12.2. Overall Product Portfolio
8.12.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.12.3. Financials
8.12.3.1. Financial Summary
8.12.4. Global Presence
8.12.5. Recent Developments
8.12.6. SWOT Analysis
8.13. Pfizer, Inc.
8.13.1. Overview
8.13.2. Overall Product Portfolio
8.13.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.13.3. Financials
8.13.3.1. Financial Summary
8.13.4. Global Presence
8.13.5. Recent Developments
8.13.6. SWOT Analysis
8.14. SANOFI
8.14.1. Overview
8.14.2. Overall Product Portfolio
8.14.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.14.3. Financials
8.14.3.1. Financial Summary
8.14.4. Global Presence
8.14.5. Recent Developments
8.14.6. SWOT Analysis
8.15. Takeda Pharmaceutical Company Limited
8.15.1. Overview
8.15.2. Overall Product Portfolio
8.15.2.1. Product Offerings for Metastatic Cancer Treatment Market
8.15.3. Financials
8.15.3.1. Financial Summary
8.15.4. Global Presence
8.15.5. Recent Developments
8.15.6. SWOT Analysis
8.16. bluebird bio, Inc.
8.16.1. Overview
8.16.2. Product Offerings for Metastatic Cancer Treatment Market
8.17. Clovis Oncology, Inc.
8.17.1. Overview
8.17.2. Product Offerings for Metastatic Cancer Treatment Market
8.18. IDERA PHARMACEUTICALS, INC.
8.18.1. Overview
8.18.2. Product Offerings for Metastatic Cancer Treatment Market
8.19. eTheRNA immunotherapies NV
8.19.1. Overview
8.19.2. Product Offerings for Metastatic Cancer Treatment Market

Report Scope and Methodology

9.1. Scope of the Report
9.2. Global Metastatic Cancer Treatment Market Segmentation
9.3. Research Methodology
9.3.1. Primary Research
9.3.2. Secondary Research
9.3.3. Key Data Points from Primary Sources 
9.3.4. Key Data Points from Secondary Sources 
9.3.5. Data Triangulation
9.3.6. Top-Down Approach (Segment Wise Analysis)
9.3.7. Bottom-Up Approach (Segmental Analysis)
9.4. Assumptions and Limitations
9.5. Data and Prediction Modelling

Annexures

10.1. Recent Key Developments and Strategies
10.2. Product Mapping
10.3. Cancer Data Sheet

List of Tables

Table 1 Total Regional Geriatric Population by Region (%), 2015 and 2030
Table 2 Impact of Market Drivers
Table 3 Impact of Market Restraints
Table 4 Market Share (2014-2017)
Table 1.1 Estimated New Cases and Estimated Deaths in 2018 as per American Cancer Society 
Table 1.2 GLOBOCAN Data as of 2012
Table 1.3 Common sites of Metastasis for Cancers
Table 1.4 Common Classes of Drugs Under Different Cancer Therapies
Table 1.5 Recent FDA Approvals of Oncology Drugs
Table 2.1 Impact of Market Drivers
Table 2.2 Impact of Market Restraints
Table 2.3 Comparison of R&D Expense 2017 and 2016
Table 2.4 Recent Approval of Metastatic Cancer Drugs 
Table 2.5 Side Effects Caused by common Metastatic Cancer Drugs 
Table 3.1 Regulatory Scenario Across the World
Table 3.2 Regulatory Designations Across The World
Table 3.3 Patent Landscape
Table 4.1 Factors Affecting the Bargaining Power of Suppliers
Table 4.2 Factors Affecting the Bargaining Power of Buyer
Table 4.3 Factors Affecting Threat of New Entrant
Table 4.4 Factors Affecting the Threat of Substitute
Table 4.5 Factors Affecting the Intensity of Competitive Rivalry
Table 4.6 Market Share of Key Players (2014-2017)
Table 4.7 Pipeline Analysis of Metastatic Cancer Treatment Drugs
Table 5.1 Estimated Incidence, Mortality, and Prevalence of Breast Cancer Worldwide in 2012
Table 5.2 Estimated Incidence and Mortality of Melanoma Worldwide in 2012
Table 5.3 Estimated Incidence, Mortality and Prevalence of Prostate Cancer Worldwide in 2012
Table 5.4 Estimated Incidence, Mortality and Prevalence of Lung Cancer (for both sexes) Worldwide in 2012
Table 5.5 Estimated Incidence, Mortality and Prevalence of Colorectal Cancer (for both sexes) Worldwide in 2012
Table 5.6  Estimated Incidence, Mortality and Prevalence of Different Cancer (for both sexes) Worldwide in 2012
Table 5.7 List of Companies and Drugs for Various Therapeutic Indication
Table 6.1 List of Common Brand-name Drugs used to treat Metastatic Cancer
Table 6.2 List of Common Generic Drugs used to treat Metastatic Cancer
Table 6.3 Sales of Oncology Drugs
Table 7.1 State-wise distribution of Cancer in India  
Table 8.1 List of Tier 1 and Tier 2 Companies
Table 8.2 AbbVie Inc.: Recent Developments
Table 8.3 Amgen, Inc.: Recent Developments 
Table 8.4 AstraZeneca PLC: Recent Developments
Table 8.5 Bayer AG: Recent Developments
Table 8.6 Boehringer Ingelheim International GmbH: Recent Developments
Table 8.7 BRISTOL-MYERS SQUIBB COMPANY: Recent Developments
Table 8.8 CELGENE CORPORATION: Recent Developments
Table 8.9  Eli-Lilly and Company: Recent Developments
Table 8.10 F. Hoffmann-La Roche AG: Recent Developments
Table 8.11 JOHNSON & JOHNSON: Recent Developments
Table 8.12 Merck & Co.,Inc. : Recent Developments
Table 8.13 Novartis AG: Recent Developments
Table 8.14 Pfizer, Inc.: Recent Developments
Table 8.15 SANOFI: Recent Developments
Table 8.16 Takeda Pharmaceutical Company Limited: Recent Developments

List of Figures

Figure 1 Common Treatments of Cancer
Figure 2 Global Metastatic Cancer Treatment Market ($Million)
Figure 3 Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2017
Figure 4 Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2025
Figure 5 Global Metastatic Cancer Treatment Market by Products, 2017
Figure 6 Global Metastatic Cancer Treatment Market By Products, 2025
Figure 7 Global Metastatic Cancer Treatment Market by Region, 2017
Figure 8 Global Injectable Drug Delivery Market by Region, 2025
Figure 1.1 Causes of Cancer
Figure 1.2 Common Mechanism of Metastasis
Figure 1.3 Types of Metastatic Cancer (based on how far it has spread)
Figure 1.4 Global Metastatic Cancer Treatment Market, 2016-2025 ($ Million)
Figure 2.1 Market Dynamics: Drivers, Restraints & Opportunities
Figure 2.2 Targeted Therapies Designed for Different Cancer Types
Figure 3.1 Industry Insights (January 2014-February 2018)
Figure 4.1 Competitive Landscape (January 2014-February 2018)
Figure 4.2 Share of Key Developments and Strategies(January 2014 to March 2018) 
Figure 4.3 Product Approvals by Companies
Figure 4.4 Clinical Study, by Companies
Figure 4.5 Product Approvals by Companies
Figure 4.6 Porter’s Five Forces Analysis
Figure 5.1 Types of Metastatic Cancer by Therapeutic Indication
Figure 5.2 Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2014-2025 ($Million)
Figure 5.3 Signs and Symptoms of Metastatic Breast Cancer
Figure 5.4 Common Molecular Subtypes of Breast Cancer
Figure 5.5 Global Metastatic Cancer Treatment Market by Breast Cancer, 2014-2025 ($ Million)
Figure 5.6 List of Common Metastatic Breast Cancer Drugs
Figure 5.7 Signs and Symptoms of Metastatic Melanoma
Figure 5.8 Global Metastatic Cancer Treatment Market by Melanoma Cancer, 2014-2025 ($ Million)
Figure 5.9 List of Common Metastatic Melanoma Cancer Drugs
Figure 5.10 Signs and Symptoms of Metastatic Prostate Cancer
Figure 5.11 Global Metastatic Cancer Treatment Market by Prostate Cancer, 2014-2025 ($ Million)
Figure 5.12 List of Common Metastatic Prostate Cancer Drugs
Figure 5.13 Signs and Symptoms of Metastatic Lung Cancer
Figure 5.14 Global Metastatic Cancer Treatment Market by NSCLC, 2014-2025 ($ Million)
Figure 5.15 List of Common Metastatic Lung Cancer Drugs
Figure 5.16 Signs and Symptoms of Metastatic Colorectal Cancer
Figure 5.17 Global Metastatic Cancer Treatment Market by Colorectal Cancer, 2014-2025 ($ Million)
Figure 5.18 List of Common Metastatic Colorectal Cancer Drugs
Figure 5.19 Global Metastatic Cancer Treatment Market by Other Cancers, 2014-2025 ($ Million)
Figure 6.1 Classification of Anti-Cancer Drugs by Pharma Class
Figure 6.2 Global Metastatic Cancer Treatment Market by Branded Medicines, 2014-2025 ($ Million)
Figure 6.3 Global Metastatic Cancer Treatment Market by Generic Medicines, 2014-2025 ($ Million)
Figure 7.1 Global Metastatic Cancer Treatment Market by Region, 2014-2025 ($Million)
Figure 7.2 North America Metastatic Cancer Treatment Market, 2014-2025 ($Million)
Figure 7.3 North America Metastatic Cancer Treatment Market  by Country, 2014-2025 ($Million)
Figure 7.4 Cancer Patient Data by Cancers Type in the U.S. (2016)
Figure 7.5 Cancer Patient Data by Cancers Type in Canada (2016)
Figure 7.6 The U.S. Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.7 Canada Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.8 Europe Metastatic Cancer Treatment Market, 2014-2025 ($Million)
Figure 7.9 Europe Metastatic Cancer Treatment Market  by Country, 2014-2025 ($Million)
Figure 7.10 Cancer Patient Data by Cancers Type in Germany (2016)
Figure 7.11 Cancer Patient Data by Cancers Type in France (2016)
Figure 7.12 Cancer Patient Data by Cancers Type in Italy (2016)
Figure 7.13 France Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.14 Germany Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.15 Italy Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.16 Netherland Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.17 Switzerland Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure  7.18 The U.K. Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.19 Spain Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.20 Sweden Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.21 Austria Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.22 Belgium Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.23 Denmark Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.24 Finland Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.25 Poland Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.26 Russia Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.27 Ireland Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.28 Rest of Europe Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.29 Asia Pacific Metastatic Cancer Treatment Market, 2014-2025 ($Million)
Figure 7.30 Asia Pacific Metastatic Cancer Treatment Market  by Country, 2014-2025 ($Million)
Figure 7.31 Cancer Patient Data by Cancers Type in China (2016)
Figure 7.32 Cancer Patient Data by Cancers Type in Japan (2016)
Figure 7.33 Cancer Patient Data by Cancers Type in India (2016)
Figure 7.35 China Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.36 Japan Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.37 India Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.38 South Korea Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.39 Australia Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.40 Bangladesh Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.41 Malaysia Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.42 New Zealand Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.43 Rest of Asia Pacific Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.44 Latin America Metastatic Cancer Treatment Market, 2014-2025 ($Million)
Figure 7.45 Latin America Metastatic Cancer Treatment Market  by Country, 2014-2025 ($Million)
Figure 7.46 Brazil Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.47 Mexico Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.48 Argentina Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.49 Rest of Latin America Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.50 Rest of the World (RoW) Metastatic Cancer Treatment Market, 2014-2025 ($Million)
Figure 7.51 Rest of the World (RoW) Metastatic Cancer Treatment Market  by Country, 2014-2025 ($Million)
Figure 7.52 Saudi Arabia Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.53 UAE Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.54 South Africa Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.55 Israel Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.56 Other Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 8.1 Contribution of Various companies
Figure 8.2 AbbVie Inc.: Overall Product Portfolio
Figure 8.3 AbbVie Inc.: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.4 AbbVie Inc.: Overall Financials (2014-2017)
Figure 8.5 AbbVie Inc.: Revenue by Geography (2014-2017)
Figure 8.6 AbbVie Inc.: Global Presence
Figure 8.7 AbbVie Inc.: SWOT Analysis
Figure 8.8 Amgen, Inc.: Overall Product Portfolio
Figure 8.9 Amgen, Inc.: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.10 Amgen, Inc. : Overall Financials (2014-2017)
Figure 8.11 Amgen, Inc. : Revenue by Geography (2014-2017)
Figure 8.12 Amgen, Inc.: Global Presence
Figure 8.13 Amgen, Inc. : SWOT Analysis
Figure 8.14 AstraZeneca PLC: Overall Product Portfolio
Figure 8.15 AstraZeneca PLC: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.16 AstraZeneca PLC: Overall Financials (2014-2017)
Figure 8.17 AstraZeneca PLC: Revenue by Product Sales (2014-2017)
Figure 8.18 AstraZeneca PLC: Revenue by Geography (2014-2017)
Figure 8.19 AstraZeneca PLC: Global Presence
Figure 8.20 AstraZeneca PLC: SWOT Analysis
Figure 8.21 Bayer AG: Overall Product Portfolio
Figure 8.22 Bayer AG: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.23 Bayer AG: Overall Financials (2014-2017)
Figure 8.24 Bayer AG: Revenue by Geography (2014-2017)
Figure 8.25 Bayer AG: Revenue by Business Segment (2014-2015)
Figure 8.26 Bayer AG: Revenue by Buisness Segment (2016-2017)
Figure 8.27 Bayer AG: Global Presence
Figure 8.28 Bayer AG: SWOT Analysis
Figure 8.29 Boehringer Ingelheim International GmbH: Overall Product Portfolio
Figure 8.30 Boehringer Ingelheim International GmbH: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.31 Boehringer Ingelheim International GmbH: Overall Financials (2014-2017)
Figure 8.32 Boehringer Ingelheim International GmbH: Revenue by Geography (2014-2017)
Figure 8.33 Boehringer Ingelheim International GmbH: Revenue by Business Segment (2014-2015)
Figure 8.34 Boehringer Ingelheim International GmbH: Revenue by Buisness Segment (2016-2017)
Figure 8.35 Boehringer Ingelheim International GmbH: Global Presence
Figure 8.36 Boehringer Ingelheim International GmbH: SWOT Analysis
Figure 8.37 BRISTOL-MYERS SQUIBB COMPANY: Overall Product Portfolio
Figure 8.38 BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.39 BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2017)
Figure 8.40 BRISTOL-MYERS SQUIBB COMPANY: Revenue by Geography (2014-2017)
Figure 8.41 BRISTOL-MYERS SQUIBB COMPANY: Global Presence
Figure 8.42 BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis
Figure 8.43 CELGENE CORPORATION: Overall Product Portfolio
Figure 8.44 CELGENE CORPORATION: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.45 CELGENE CORPORATION: Overall Financials (2014-2017)
Figure 8.46 CELGENE CORPORATION: Revenue by Geography (2014-2017)
Figure 8.47 CELGENE CORPORATION: Global Presence
Figure 8.48 CELGENE CORPORATION: SWOT Analysis
Figure 8.49 Eli-Lilly and Company: Overall Product Portfolio
Figure 8.50 Eli-Lilly and Company: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.51 Eli-Lilly and Company: Overall Financials (2014-2017)
Figure 8.52 Eli-Lilly and Company: Revenue by Business segment (2014-2017)
Figure 8.53 Eli-Lilly and Company: Revenue by Geography (2014-2017)
Figure 8.54 Eli-Lilly and Company: Global Presence
Figure 8.55 Eli-Lilly and Company: SWOT Analysis
Figure 8.56 F. Hoffmann-La Roche AG: Overall Product Portfolio
Figure 8.57 F. Hoffmann-La Roche AG: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.58 F. Hoffmann-La Roche AG: Overall Financials (2014-2017)
Figure 8.59 F. Hoffmann-La Roche AG: Product Sales by Region (2014-2017)
Figure 8.60 F. Hoffmann-La Roche AG: Revenue by Division (2014-2017)
Figure 8.61 F. Hoffmann-La Roche AG: Revenue by Pharmaceutical Sub-Segment (2014-2017)
Figure 8.62 F. Hoffmann-La Roche AG: Global Presence
Figure 8.63 F. Hoffmann-La Roche AG: SWOT Analysis
Figure 8.64 JOHNSON & JOHNSON: Overall Product Portfolio
Figure 8.65 JOHNSON & JOHNSON: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.66 JOHNSON & JOHNSON: Overall Financials (2014-2017)
Figure 8.67 JOHNSON & JOHNSON: Revenue by Business segment (2014-2017)
Figure 8.68 JOHNSON & JOHNSON: Revenue by Geography (2014-2017)
Figure 8.69 JOHNSON & JOHNSON: Global Presence
Figure 8.70 JOHNSON & JOHNSON: SWOT Analysis
Figure 8.71 Merck & Co., Inc.: Overall Product Portfolio
Figure 8.72 Merck & Co., Inc.: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.73 Merck & Co., Inc.: Overall Financials (2014-2017)
Figure 8.74 Merck & Co., Inc.: Revenue by Business segment (2014-2017)
Figure 8.75 Merck & Co., Inc.: Revenue by Geography (2014-2017)
Figure 8.76 Merck & Co., Inc.: Global Presence
Figure 8.77 Merck & Co., Inc.: SWOT Analysis
Figure 8.78 Novartis AG: Overall Product Portfolio
Figure 8.79 Novartis AG: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.80 Novartis AG: Overall Financials (2014-2017)
Figure 8.81 Novartis AG: Revenue by Geography (2014-2017)
Figure 8.82 Novartis AG: Revenue by Business Segment (2014-2015)
Figure 8.83 Novartis AG: Revenue by Buisness Segment (2016-2017)
Figure 8.84 Novartis AG: Global Presence
Figure 8.85 Novartis AG: SWOT Analysis
Figure 8.86 Pfizer, Inc.: Overall Product Portfolio
Figure 8.87 Pfizer, Inc.: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.88 Pfizer, Inc.: Overall Financials (2014-2017)
Figure 8.89 Pfizer, Inc.: Revenue by Business segment (2014-2017)
Figure 8.90 Pfizer, Inc.: Revenue by Geography (2014-2017)
Figure 8.91 Pfizer, Inc.: Global Presence
Figure 8.92 Pfizer, Inc.: SWOT Analysis
Figure 8.93 SANOFI: Overall Product Portfolio
Figure 8.94 SANOFI: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.95 SANOFI: Overall Financials (2014-2017)
Figure 8.96 SANOFI: Revenue by Business Segment (2014-2015)
Figure 8.97 SANOFI: Revenue by Business Segment (2016-2017)
Figure 8.98 SANOFI: Revenue by Geography (2014-2015)
Figure 8.99 SANOFI: Revenue by Geography (2016-2017)
Figure 8.100 SANOFI: Global Presence
Figure 8.101 SANOFI: SWOT Analysis
Figure 8.102 Takeda Pharmaceutical Company Limited: Overall Product Portfolio
Figure 8.103 Takeda Pharmaceutical Company Limited: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.104 Takeda Pharmaceutical Company Limited: Overall Financials (2014-2017)
Figure 8.105 Takeda Pharmaceutical Company Limited: Revenue by Business segment (2014-2017)
Figure 8.106 Takeda Pharmaceutical Company Limited: Revenue by Geography (2014-2017)
Figure 8.107 Takeda Pharmaceutical Company Limited: Global Presence
Figure 8.108 Takeda Pharmaceutical Company Limited: SWOT Analysis
Figure 8.109 bluebird bio, Inc.: Product Pipeline for Cancer Treatment Market
Figure 8.110 Clovis Oncology, Inc.: Product Pipeline for Cancer Treatment Market
Figure 8.111 IDERA PHARMACEUTICALS, INC.: Product Pipeline for Cancer Treatment Market 
Figure 8.112 eTheRNA immunotherapies NV: Product Pipeline for Cancer Treatment Market
Figure 9.1 Global Metastatic Cancer Treatment Market Segmentation
Figure 9.2 Considered Factors for Data Prediction & Modeling

You may also like

Published Year: 2017

Global Cancer Imaging Systems Market - Analysis and Forecast (2017-2025): Focus on Products (Analog

The global cancer imaging systems is expected to reach $11 billion by...

 

Global Metastatic Cancer Treatment Market

Focus on Drugs, Competitive Landscape, and Country - Analysis and Forecast (2018-2025)